Cue Biopharma, Inc. CUE

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
54/100
Moderate

Ranked against 712 peers in Biotechnology

About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, … Full CUE analysis →

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.86), demonstrating competitive advantages.
  • Cash Generation Consistent Cash generation is consistent (score 0.73), indicating reliable business model.

Key risks

  • ROIC Below WACC or Peers ROIC at 37.2th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.38), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
42
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CUE ranks in Biotechnology

Cue Biopharma, Inc. ranks #186 of 713 scored companies in Biotechnology by moat score — the top 26%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
182 Fennec Pharmaceuticals Inc. FENC 55/100 Moderate
183 Axsome Therapeutics, Inc. AXSM 54/100 Moderate
184 Inhibikase Therapeutics, Inc. IKT 54/100 Moderate
185 REGENXBIO Inc. RGNX 54/100 Moderate
186 Cue Biopharma, Inc. CUE 54/100 Moderate
187 Lineage Cell Therapeutics, Inc. LCTX 54/100 Moderate
188 Fulcrum Therapeutics, Inc. FULC 54/100 Moderate
189 Liquidia Corporation LQDA 54/100 Moderate
190 ProQR Therapeutics N.V. PRQR 54/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How CUE scores on the Corporate Default defenses

Pricing Power

Score 42 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 75 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 59 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 31 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 44 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 84 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CUE's moat

What is Cue Biopharma, Inc.'s moat score?

Cue Biopharma, Inc. (CUE) scores 54 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #186 of 713 scored companies in Biotechnology, the top 26%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (84/100) and its weakest is Capital Efficiency (31/100).

How does Cue Biopharma, Inc. compare with other Biotechnology companies?

Cue Biopharma, Inc. ranks #186 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are REGENXBIO Inc. (RGNX) at 54 just above it and Lineage Cell Therapeutics, Inc. (LCTX) at 54 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Cue Biopharma, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Cue Biopharma, Inc.?

The Corporate Default template measures 6 defenses, and CUE scores: Pricing Power (42), Cost Advantage (75), Customer Stickiness (59), Capital Efficiency (31), Resilience (44), Scale & Market Position (84). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000